IDT Biologika's revenue in 2023 was 275 million euros ($297 million), experiencing a decline from its record revenue of 312 million euros ($328 million) achieved in 2022.
IDT Biologika's Financial Performance
In 2022, IDT Biologika reached a record high in its revenue, primarily propelled by its involvement in the production of COVID vaccines. However, the company saw a decrease in sales in 2023. This financial overview highlights the company's recent performance:| Year | Revenue (Euros) | Revenue (USD) | Notes |
|---|---|---|---|
| 2022 | €312 million | $328 million | Record revenue, fueled by COVID vaccine production |
| 2023 | €275 million | $297 million | Sales slumped from the previous year |
IDT Biologika is a global player in the biopharmaceutical industry, with operations spanning Germany and the U.S. The company maintains a substantial workforce, employing approximately 1,800 individuals.
